Rodman & Renshaw Reiterates Buy Rating on CorMedix (CRMD), PT $20, 'weakness today is likely overdone'
Tweet Send to a Friend
Rodman & Renshaw analyst Brandon Folkes reiterated a Buy rating and $20.00 price target on CorMedix (NASDAQ: CRMD)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
